ViGene Biosciences product launch- introducing the largest collection of premade human full-length cDNA ORF and miRNA adenoviruses
November 6, 2013 (Newswire) - ViGene Biosciences, Inc., a leading viral gene-delivery systems provider, today announces the launch of its world's largest collection of premade human full-length cDNA ORF and miRNA adenoviruses. The collection features over 1,200 pre-packaged human miRNA precursor clones and 6,000 human full-length cDNA clones. Its introduction will significantly boost high throughput drug discovery, support functional genomic studies, and make life science research more efficient and cost-effective.
Recombinant adenoviruses are extremely efficient gene delivery systems that are widely used in human gene therapy and in vitro gene functional studies. Compared with lentiviral vector, transfection with adenovirus can reach 100% (vs. 30% with lentivirus), and protein expression can reach up to 10-20% of the total protein. Traditionally, adenoviral vector cloning and virus production requires up to 4-6 weeks, time required may significantly reduce operational efficiency. The creation of this genome-wide premade adenoviruses collection that is readily available will benefit researchers who work with difficult-to-transfect primary cells and stem cells, as well as any other researchers who use full-length cDNA clones.
"Our strength is not only the innovative technology for adenoviral vector production, but also the capability to create the most comprehensive collection of human full-length cDNA clones in the world," said Dr. Ying Chen, Vice President of Research and Development of ViGene Biosciences, Inc. "The biotech industry has been depending heavily on the MGC (Mammalian Gene Collection) for full-length cDNA clones, but the MGC only contains 13,000 full-length cDNA clones. Of the 19,000 unique genes (loci) in the human genome, we have systematically generated 18,000 full-length cDNA templates representing 18000 unique loci. Each of these cDNAs will be cloned into our adenoviral vector to produce ready-to-use adenoviruses." noted Dr. Chen. "We are thrilled to have this near-complete genome-wide premade adenovirus collection. It will greatly accelerate genome-wide high throughput drug screening and development, cell-based assays, and many aspects of gene function studies."
In addition to the adenoviral vectors, ViGene has also developed lentiviral and adeno-associated viral (AAV) vectors. Upon completion of the genome-wide adenovirus production, ViGene is excited to further transfer the same set of full-length cDNA ORFs into lentiviral vector and AAV vector to create an even broader premade virus collection. ViGene's largest premade virus collection will represent the next generation gene products for advancing life science research.